GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice DOI Creative Commons
Robert M. Gutgesell, Ahmed Khalil, Arkadiusz Liśkiewicz

et al.

Nature Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Language: Английский

Glucose-dependent insulinotropic polypeptide (GIP) DOI Creative Commons
Timo D. Müller, Alice E. Adriaenssens,

Bo Ahrén

et al.

Molecular Metabolism, Journal Year: 2025, Volume and Issue: 95, P. 102118 - 102118

Published: Feb. 28, 2025

Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in maintenance of glucose tolerance healthy humans. Until recently GIP had not been developed as a therapeutic thus has overshadowed by other incretin, glucagon-like peptide 1 (GLP-1), which is basis for several successful drugs to treat diabetes obesity. However, there rekindling interest biology recent years, great part due pharmacology demonstrating that both GIPR agonism antagonism may be beneficial treating obesity diabetes. This apparent paradox reinvigorated field, led new lines investigation, deeper understanding GIP. In this review, we provide detailed overview on multifaceted nature discuss implications signal modification various diseases. Following its classification hormone, emerged pleiotropic hormone with variety metabolic effects outside endocrine pancreas. The numerous render interesting candidate development pharmacotherapies obesity, diabetes, drug-induced nausea bone neurodegenerative disorders.

Language: Английский

Citations

3
The role of GIPR in food intake control DOI Creative Commons

Paula-Peace James-Okoro,

Jo E. Lewis, Fiona M. Gribble

et al.

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 16

Published: March 17, 2025

Glucose-dependent insulinotropic polypeptide (GIP) is one of two incretin hormones playing key roles in the control food intake, nutrient assimilation, insulin secretion and whole-body metabolism. Recent pharmacological advances clinical trials show that unimolecular co-agonists target receptors for incretins - GIP glucagon-like peptide 1 (GLP-1) offer more effective treatment strategies obesity type 2 diabetes mellitus (T2D) compared with GLP-1 receptor (GLP1R) agonists alone, suggesting previously underappreciated regulating intake body weight. The mechanisms by which regulates energy balance remain controversial as both agonism antagonism (GIPR) produce weight loss improve metabolic outcomes preclinical models. studies have shown GIPR signalling central nervous system (CNS), especially regions brain regulate balance, essential its action on appetite regulation. This finding has sparked interest understanding engages circuits to reduce In this review, we present knowledge around actions regulation potential GIPR/GLP1R may balance.

Language: Английский

Citations

0
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice DOI Creative Commons

Clarissa M. Liu,

Elizabeth A. Killion, Rola Hammoud

et al.

Nature Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Language: Английский

Citations

0
Unravelling the GIPR agonist versus antagonist paradox DOI
Alice E. Adriaenssens

Nature Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Language: Английский

Citations

0
GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice DOI Creative Commons
Robert M. Gutgesell, Ahmed Khalil, Arkadiusz Liśkiewicz

et al.

Nature Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Language: Английский

Citations

0